Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

NeuroVive Raises $3 Million for Taiwan Subsidiary; Plans IPO

publication date: Feb 11, 2015
NeuroVive, a Swedish clinical-stage pharma focused on drugs that protect mitochondrial function, established a subsidiary in Taiwan and raised $3.3 million for the venture. The company previously announced it would IPO the new company, NeuroVive Pharmaceutical Asia, Inc., on the Taiwan stock exchange. NeuroVive Asia holds the Asian rights (ex-China) to NeuroVive's two clinical stage projects, which address cerebral-cardiovascular problems. In 2012, NeuroVive out-licensed China rights for the drugs to Sihuan Pharma. More details....

Stock Symbols: (STO: NVP) (HK: 0460)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China